Thrombocytopenia as a marker of outcome in patients with acute exacerbation of chronic obstructive pulmonary disease by Rahimi-Rad, Mohammad Hossein et al.
www.pneumonologia.viamedica.pl
PRACA ORYGINALNA
348
O IGINAL RESE RCH
Address for correspondence: Mohammad Hossein Rahimi-Rad, Department of Medicine, College of Medicine, Urmia University of Medical Sciences, Iran, s.rahimirad@hotmail.com
DOI: 10.5603/PiAP.2015.0056
Received: 17.12.2014
Copyright © 2015 PTChP
ISSN 0867–7077
Mohammad Hossein Rahimi-Rad1, Sheida Soltani2, Masome Rabieepour1, Shagayegh Rahimirad3
1Department of Medicine, College of Medicine, Urmia University of Medical Sciences, Iran
2Urmia University of Medical Sciences, Iran
3Tabriz University of Medical Sciences, Tabriz, Iran
Thrombocytopenia as a marker of outcome in patients with acute 
exacerbation of chronic obstructive pulmonary disease
The authors declare no financial disclosure
Abstract
Introduction: Thrombocytopenia (TP) is associated with poor outcome in patients who are critically ill with pneumonia, burns, and 
H1N1 influenza. To our knowledge, no similar study in patients with acute exacerbation of chronic obstructive pulmonary disease 
(AECOPD) has been conducted to date. The aim of this study was to determine the impact of platelet count on the outcome of 
patients with AECOPD. 
Material and methods: Patients admitted to our teaching hospital for AECOPD were divided into two cohorts, those with and 
without TP. The outcome of all patients was followed. 
Results: Of the 200 patients with AECOPD, 55 (27.5%) had TP. Of these, 14 (25.5%) died in the hospital, whereas of the 145 non-TP 
patents, 11 (7.5%) died (p-value = 0.001). There was a significantly higher transfer rate to the ICU and mechanical ventilation 
in TP patients. The mean platelet count was significantly lower in patients who died than those who were discharged (161,672 
vs. 203,005 cell/µL; p-value = 0.017). There was negative correlation between duration of hospitalization and platelet count. 
Conclusion: TP was associated with poor outcome in AECOPD. TP could be considered as a marker for the assessment of inflam-
mation and prognosis in AECOPD patients based on its cost-effective features.
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Introduction
The chronic obstructive pulmonary disease 
(COPD) is an important cause of morbidity and 
mortality worldwide and a new prediction is 
that COPD will be the fourth leading cause of 
death in 2030 [1]. COPD is currently considered 
as a systemic disorder that is associated with an 
increased risk of diabetes mellitus, hypertension, 
and cardiovascular disease [an independent risk 
factor] [2, 3]. The suggested mechanisms for these 
associations include hypoxia, oxidative stress, 
and systemic inflammation in COPD [4, 5].
COPD is characterized by episodic increases 
in respiratory symptoms known as acute exac-
erbations of COPD (AECOPD). AECOPDs are 
associated with an increase in local and systemic 
inflammation, which may lead to an acute car-
diovascular event [6]. 
Identification of patients that may show 
a  poor prognosis with any disease including 
AECOPD is important because it could lead to 
more appropriate therapeutic interventions. Some 
biomarkers are used to predict AECOPD patient 
outcome, however, these may require additional 
tests and thus additional expenses, and might not 
be available at every center or at any time. Com-
plete blood count (CBC) is an inexpensive, com-
mon laboratory test. In addition to their role in 
hemostasis, platelets regulate an inflammatory re-
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Table 1. Comparison of poor outcome parameters between thrombocytopenic and non-thrombocytopenic patients
TP Non-TP Total P value Risk ratio
Died in hospital n (%) 14 (25.0) 11 (7.6) 25 (12.5) 0.001 4.16 (1.75−9.86)
Mechanical ventilation n (%) 17 (30.9) 21 (14.5) 38 (19) 0.008 2.64 (1.26−5.12)
Need ICU n (%) 19 (34.5) 20 (13.8) 39 (19.5) 0.001 1.51 (1.10−2.07)
 TP — thrombocytopenia patients, Non-TP — non-thrombocytopenic patients
Figure1. Correlation of duration of hospitalization (in days) with plate-
let count
sponse. In the CBC test, thrombocytosis is used as 
a marker of acute phase reaction. However, throm-
bocytopenia (TP) has recently been recognized 
as a prognostic marker in a variety of acute and 
critical diseases, including H1N1 influenza [7], 
community acquired pneumonia [8], acute kid-
ney injury [9, 10], burns [11, 12], as well as in 
both pediatric and adult critically ill patients 
[13, 14]. TP may reflect some pathophysiologic 
disturbances, including disseminated intravas-
cular coagulation, sepsis, macrophage activation, 
vitamin deficiencies, drug-induced toxicity, and 
unidentified factors [14]. AECOPD is also associ-
ated with an accelerated decline of lung function, 
impaired health status, reduced physical activity, 
and increased mortality. To our knowledge, the 
effect of TP on AECOPD mortality has not been in-
vestigated till date. The advantage of using plate-
lets as a predictor of AECOPD patient outcome 
is that it is readily available in routine complete 
blood count (CBC),  and does not entail additional 
expenses for its testing. The aim of this study was 
therefore to determine the correlation between TP 
and hospital mortality due to AECOPD. 
Material and methods
Medical records of 200 patients with initial 
and final diagnoses of AECOP were reviewed. 
On the bases of platelet count on admission 
day, the patients were divided into two cohorts, 
namely, patients with TP and those without. 
Patient outcome and duration of hospitaliza-
tion were recorded. Thrombocytopenia was 
defined as a  platelet count of < 150,000/µL. 
Poor outcome was defined as death during the 
hospital stay, a need to transfer to the intensive 
care units (ICU), or intubation with or without 
mechanical ventilation. The following patients 
were excluded from the study: a) patients with 
recorded concomitant hematologic or oncologic 
disease or any disease affecting platelet counts, 
b) patients without CBC tests performed on ad-
mission day, and c] an initial or final diagnosis 
other than AECOPD.
Chi-square test was used to compare the 
prevalence of TP between patients who died due 
to AECOPD and those that survived. Continuous 
variables were presented as the mean ± SD and 
were compared using the student’s t-test. A p-val-
ue < 0.05 was considered statistically significant. 
These analyses were performed with SPSS 19 
IBM version.
Results
We studied 200 patients (122 males, 61%; 78 
females, 39%). The study population had a mean 
age of 68.92 ± 11.47 years. Of the 200 patients 
with AECOPD, 25 (12.5%) died in the hospital 
and 55 (27.5%) had TP. A statistically higher per-
centage of patients with TP died in the hospital, 
as well as required mechanical ventilation and 
care at the ICU (Table 1). Platelet count was sig-
nificantly lower among patients who died in the 
hospital (mean ± SD = 161,672.00 ± 81,266.268) 
compared to the patients who survived the dis-
ease (mean ± SD = 203,005.71 ± 79,887.600 
cell/µL), with a p-value = 0.017. Patients with TP 
had a longer hospital stay (mean: 10.47 days vs. 
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7.68 days, p = 0.027). Duration of hospitalization 
was inversely correlated with platelet count (R = 
0.061; Fig. 1).
Discussion
This cohort study clearly showed a signifi-
cant correlation between TP and higher mortality 
in patients with AECOPD. It is well known that 
white blood cells play an important role in host 
defense against pathogenic organisms [15]; these 
cells can recruit leukocytes and progenitor cells to 
sites of inflammation. Platelet granules store and 
secrete a number of bioactive substances, which, 
in addition to platelet aggregation and coagula-
tion, cause chemotaxis, neutrophil and monocyte 
adhesion, and cell survival and proliferation [16]. 
Platelets are involved in inflammation, athero-
genesis, and atherothrombosis. Platelets have im-
mune system-modulating properties and promote 
the release of chemokines and cytokines. Platelets 
interact with each other and with monocytes and 
neutrophils [9]. 
There are no similar studies involving COPD 
patients to which we could compare our results. 
Lopez-Delgado et al. [7] reported that in patients 
with H1N1 influenza, TP at admission was as-
sociated with a  lower survival rate (55% vs. 
92.5%). They suggested that the presence of TP 
was indicative that the immune system elicited 
an inadequate response to the H1N1 infection. In 
another study involving patients with commu-
nity-acquired pneumonia, those with TP more 
often presented with severe sepsis, septic shock, 
ICU admission, and the need for invasive me-
chanical ventilation [17]. TP was associated with 
higher mortality in acute kidney injury patients 
requiring dialysis [18]. 
Previous reports have demonstrated that 
a prothrombotic condition exists in COPD, where-
as others described an increase in platelet activa-
tion in COPD patients. Elevated platelet arginase 
activity is usually observed in COPD patients and 
this is due to alterations in nitric oxide metabo-
lism [19]. Ferroni et al. [20] showed that soluble 
P-selectin, a marker of platelet hyperactivity, was 
higher in COPD patients. COPD patients show 
a higher number of platelet-monocyte aggregates, 
which is indicative of platelet activation; this fur-
ther increases in AECOPD [21]. Ashitani et al. [22] 
reported an increase in a marker of platelet ac-
tivation (beta-thromboglobulin) and markers of 
coagulation-fibrinolysis-system (fibrinopeptide 
A, thrombin antithrombin III complex, and tis-
sue plasminogen activator-plasminogen activator 
inhibitor) in 40 COPD patients compared to the 
control group. They concluded that this clotting 
factor is an independent predictor of an acute 
exacerbation [22]. During AECOPD, an exagger-
ated shift in the hemostatic balance occurs due 
to an increase in platelet aggregation, which was 
caused by acute disturbances in gas exchange 
and hypoxemia. This enhanced platelet activity 
directly damages lung vessels and/or induces the 
release of mediators [23, 24].
A possible explanation for the association be-
tween poor prognosis and TP is that TP might be 
a marker of bacterial infection and sepsis, causing 
a higher morbidity rate in AECOPD patients with 
TP. Sepsis is the leading cause of TP in critically 
ill patients [25].
The important limitation of this study is that 
the investigation was conducted at a single center. 
This significantly limits the generalizability of our 
results. Further studies are necessary, in partic-
ular with focusing on investigating the cause of 
death in AECOPD patients with TP. In addition 
better understanding of the role of platelets in the 
outcomes of patients with AECOPD may generate 
new therapeutic modalities for COPD.
Conclusions
1. TP was associated with poor AECOPD patient 
outcome. 
2. TP could be considered as a marker for the 
assessment of inflammation and prognosis in 
AECOPD patients based on its cost-effective 
features.
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